CLINUVEL today announced its second Strategic Update, focussing on the decision processes underlying choices to expand and grow the Group of companies. A main goal of CLINUVEL’s growth is to integrate skills and functions in-house within the Group. Explore the Strategic Update II in detail below or download a full PDF summary here.
CLINUVEL’s CEO, Dr. Philippe Wolgen, provides an update on the business, vision, objectives and strategy.
“The vision has always been to establish a company that’s diversified, sustainable, and fully integrated, with all functions in-house”
The corporate objective is to establish a globally sustainable group with a constellation of prescriptive and healthcare products derived from melanocortins, originated from associated pharmacological concepts and addressing populations who yet remain unserved.
CLINUVEL strives for vertical integration of all key functions to ensure operational and financial independence, and synergy within the Group of companies.
CLINUVEL has focussed its R&D on melanocortins, associated hormones and peptides, polymers and technological expertise to
be applied for human use.
It is estimated that, globally, two billion individuals are susceptible to accelerated photodamage, leading to an increased risk of various forms of skin cancer.
Scientific progress has demonstrated melanocortins as hormonal therapy to exert a positive effect on the central nervous system (CNS).
SCENESSE® is being evaluated as the first systemically administered melanocortin for the pigment loss disorder, generalized vitiligo.
Under the notion of Targeted Technology Translation (TTT), CLINUVEL aims to make technology, knowhow and expertise available for the greater benefit of broad populations.
The CBM Division is responsible for composing unique narratives and engaging in long-term dialogue with new audiences.